Hypoglycemia Market Poised for Notable Growth by 2032, Fueled by Innovation and FDA Breakthrough for Rezolute’s Ersodetug | Eiger BioPharmaceuticals, MBX Biosciences, Hanmi Pharmaceutical, and others.
DelveInsight’s latest 7MM report, “Hypoglycemia Market Report,” provides a comprehensive analysis of market trends, epidemiological insights, and emerging therapies. The report covers detailed forecasts and unmet needs across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, offering strategic guidance to stakeholders.
Some of the key facts of the Hypoglycemia Market Report:
• The total hypoglycemia market size is estimated to grow with a significant CAGR during the study period (2019-2032).
• Approximately 57.44% of diabetes patients experience hypoglycemia, with nearly 11% encountering severe episodes.
• The age-standardized proportion of hypoglycemia-related deaths is 4.49 per 1,000 total diabetes deaths across 109 countries.
• In the United States, severe hypoglycemia is associated with a 3.4-fold increase in 5-year mortality among diabetes patients.
• In the U.S., approximately 2–5% of hospitalized patients with diabetes mellitus experience severe hypoglycemia.
• In May 2025, Rezolute, Inc. (Nasdaq: RZLT) announced that the FDA granted Breakthrough Therapy Designation to its investigational drug, Ersodetug, for treating hypoglycemia caused by tumor-induced hyperinsulinism (HI).
• In March 2025, Xeris Biopharma Holdings, Inc. announced that its supplemental new drug application (sNDA) for Gvoke VialDx™ received FDA approval for use as a diagnostic aid during radiologic exams to temporarily inhibit gastrointestinal tract movement in adult patients.
• In September 2024, Rezolute, Inc. announced that the FDA has lifted the partial clinical holds on RZ358 (ersodetug), its novel therapy for treating hypoglycemia in patients with congenital hyperinsulinism (HI). This marks a significant step forward in developing this potential treatment for the rare disease.
• Leading hypoglycemia therapies include Avexitide, MBX 1416, HM 15136, TB 222 023, and others.
• Leading companies in the hypoglycemia market include Eiger BioPharmaceuticals, MBX Biosciences, Hanmi Pharmaceutical, Twist Bioscience, and others.
To know in detail about the hypoglycemia market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Hypoglycemia Market Forecast
Hypoglycemia Overview
Hypoglycemia, commonly known as low blood sugar, is a condition where the glucose levels in the bloodstream drop below normal, typically below 70 mg/dL. It is most commonly associated with diabetes, particularly in patients who are on insulin or other medications that increase insulin production. However, hypoglycemia can also occur in people without diabetes due to factors such as prolonged fasting, excessive alcohol consumption, or certain medical conditions.
The symptoms of hypoglycemia include shaking, sweating, confusion, dizziness, weakness, and in severe cases, loss of consciousness, seizures, and even death. If left untreated, severe hypoglycemia can be life-threatening. The condition is typically managed by consuming fast-acting carbohydrates, such as glucose tablets or sugary drinks, to raise blood sugar levels quickly.
Hypoglycemia is a significant concern for individuals with diabetes as it can lead to dangerous fluctuations in blood sugar, increasing the risk of both short-term and long-term complications. As a result, effective monitoring, personalized treatment plans, and ongoing management are critical to minimize the risk of hypoglycemia in diabetic patients. Research into treatments and therapies for hypoglycemia is ongoing, with promising developments aimed at improving patient outcomes.
Get a free sample for the hypoglycemia market report:https://www.delveinsight.com/report-store/hypoglycemia-market
Hypoglycemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hypoglycemia Epidemiology Segmentation:
The hypoglycemia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Type-specific Bariatric Surgery Cases
• Total Postbariatric Hypoglycemia (PBH) Cases
• Postbariatric Hypoglycemia (PBH) Cases in types of Bariatric Surgeries
• Severity-specific Postbariatric Hypoglycemia (PBH) Cases
• Total Treated Cases of Postbariatric Hypoglycemia (PBH) Cases
Download the report to understand which factors are driving hypoglycemia epidemiology trends at Hypoglycemia Epidemiology Forecast
Hypoglycemia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the hypoglycemia market or expected to be launched during the study period. The analysis covers the hypoglycemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the hypoglycemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing, patent details, and other information for emerging therapies.
Hypoglycemia Market Strengths
• The rising number of diabetes cases worldwide increases the demand for hypoglycemia treatments, creating a large market for related therapies.
• Ongoing innovations in hypoglycemia management, including the development of new drugs and technologies, are enhancing treatment options and improving patient outcomes.
Hypoglycemia Market Weaknesses
• The cost of advanced hypoglycemia treatments, particularly for rare causes like tumor hyperinsulinism, can be prohibitive for many patients, limiting market accessibility.
• There is a lack of awareness about hypoglycemia outside of diabetes management, which may hinder the identification of potential patients and slow market growth in non-diabetic hypoglycemia cases.
Scope of the Hypoglycemia Market Report
• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hypoglycemia Companies: Eiger BioPharmaceuticals, MBX Biosciences, Hanmi Pharmaceutical, Twist Bioscience, and others.
• Key Hypoglycemia drugs: Avexitide, MBX 1416, HM 15136, TB 222 023, and others.
• Hypoglycemia Therapeutic Assessment: Hypoglycemia currently marketed, and Hypoglycemia emerging therapies
• Hypoglycemia Market Dynamics: Hypoglycemia market drivers and Hypoglycemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Hypoglycemia Unmet Needs, KOL’s views, Analyst’s views, Hypoglycemia Market Access and Reimbursement
To learn more about the key players and advancements in the hypoglycemia treatment landscape, visit the Hypoglycemia Market Analysis Report
Table of Contents
1. Hypoglycemia Market Report Introduction
2. Executive Summary for Hypoglycemia
3. SWOT analysis of Hypoglycemia
4. Hypoglycemia Patient Share (%) Overview at a Glance
5. Hypoglycemia Market Overview at a Glance
6. Hypoglycemia Disease Background and Overview
7. Hypoglycemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypoglycemia
9. Hypoglycemia Current Treatment and Medical Practices
10. Hypoglycemia Unmet Needs
11. Hypoglycemia Emerging Therapies
12. Hypoglycemia Market Outlook
13. Country-Wise Hypoglycemia Market Analysis (2019–2032)
14. Hypoglycemia Market Access and Reimbursement of Therapies
15. Hypoglycemia Market Drivers
16. Hypoglycemia Market Barriers
17. Hypoglycemia Appendix
18. Hypoglycemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
